To obtain an oral preparation useful for chronic cardiac insufficiency, excellent in shelf stability of a forskolin derivative salt, by using both the forskolin derivative and a specific alkali metal compound.
This oral preparation comprises a forskolin derivative salt and a halogenated alkali metal as medicinal components. A compound of the formula [R1 is H; R4 is vinyl, ethyl or cyclopropyl; one of R2 and R3 is CO (CH2)mNR5R6 (R5 and R6 are each H, an alkyl or R5 and R6 are bonded to form an alkylene; (m) is 1-5) and the other is H or CO(CH2)nX [X is NR7R8 (R7 and R8 are each H, an alkyl, etc.); (n) is 1-5]] is preferable as the forskolin salt. Sodium chloride or potassium chloride is preferable as the halogenated alkali metal. The amount of the halogenated alkali metal is preferably 0.01-26 pts.wt. based on 1 pt.wt. of the forskolin derivative.
YAHIRO TOMIO
YOSHIDA HIROYUKI
